Lataa...
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative neoplasms associated with somatic hematopoietic stem cell mutations leading to over activation of JAK–STAT signaling. MF and PV are pathogenically related and share specific clinical features such as splenomegaly...
Tallennettuna:
| Julkaisussa: | Cancer Chemother Pharmacol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4882345/ https://ncbi.nlm.nih.gov/pubmed/27017614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3012-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|